메뉴 건너뛰기
Clinical Pharmacokinetics
Volumn 40, Issue 7, 2001, Pages 523-537
Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole
Author keywords

[No Author keywords available]
Indexed keywords

AMOXICILLIN; CAFFEINE; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DIAZEPAM; DIGOXIN; ESOMEPRAZOLE; KETOCONAZOLE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PROTON PUMP INHIBITOR; QUINIDINE; WARFARIN;
EID: 0034904673     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140070-00004     Document Type: Review
Times cited : (111)
References (6)
  • 1
    • 0029977698 scopus 로고    scopus 로고
    • Pharmacokinetics, metabolism and interactions of acid pump inhibitors: Focus on omeprazole, lansoprazole, and pantoprazole
    • Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole, and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28
    • (1996) Clin Pharmacokinet , vol.31 , pp. 9-28
    • Andersson, T.1
  • 2
    • 0029083823 scopus 로고
    • Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status
    • Yasuda S, Horai Y, Tomono Y, et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 1995; 58: 143-54
    • (1995) Clin Pharmacol Ther , vol.58 , pp. 143-154
    • Yasuda, S.1    Horai, Y.2    Tomono, Y.3
  • 3
    • 0031910445 scopus 로고    scopus 로고
    • Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
    • Andersson T, Holmberg J, Röhss K, et al. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 1998; 45: 369-75
    • (1998) Br J Clin Pharmacol , vol.45 , pp. 369-375
    • Andersson, T.1    Holmberg, J.2    Röhss, K.3
  • 4
    • 0000683382 scopus 로고    scopus 로고
    • Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole (O) and its 2 optical isomers, S-omeprazole/Esomeprazole (E) and (R)-omeprazole (R-O) [abstract 5551]
    • Andersson T, Bredberg E, Sunzel M, et al. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole (O) and its 2 optical isomers, S-omeprazole/Esomeprazole (E) and (R)-omeprazole (R-O) [abstract 5551]. Gastroenterology 2000; 118 (4 Pt II): A1210
    • (2000) Gastroenterology , vol.118 , Issue.2-4 PART
    • Andersson, T.1    Bredberg, E.2    Sunzel, M.3
  • 6
    • 0033947414 scopus 로고    scopus 로고
    • Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease
    • Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-7
    • (2000) Aliment Pharmacol Ther , vol.14 , pp. 861-867
    • Lind, T.1    Rydberg, L.2    Kyleback, A.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.